Adriforant
As of the edition of 20 October 2026, Adriforant is a small molecule: stopped in 2020; acts on HRH4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2020
- Kind
- Small molecule
- Registered trials
- 6, 2 stopped early
- Disease areas
- Immune system; Skin and connective tissue; Inherited and neonatal; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route A because of this drug.
Companies on route A for this drug
In the product3 companies are on route A because of Adriforant.
See the 3 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HRH4 | Histamine H4 receptor | Q9H3N8 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 4 | 2 | 0 | 2 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pfizer | Lead sponsor of trials | 2009 to now |
| Ziarco Pharma | Lead sponsor of trials | 2015 to now |
| Novartis | Lead sponsor of trials | 2018 to now |